Authors
Latest:
How to Keep Out of Regulatory QuicksandOIG now requires corporate marketing departments and field sales reps to not only document how they promote products, but to also-for the first time-demonstrate the "intent" of marketing activities.
Latest:
Generics Battle Heats UpThe competition for generics' 180-day marketing exclusivity is fierce, and Dr. Reddy's Laboratories filed the first court case calling into question FDA's methods for determining exclusivity on a patent-by-patent basis.
Latest:
When Accessing Healthcare Value is in the Eye of the BeholderAs patients pay more healthcare expenses directly from their own pockets, the industry must look at patients' ability to pay alongside willingness to pay to understand the various factors of patient decisions to accept or decline treatment.
Latest:
Protecting IP Throughout the Product LifecycleNow that patents on several blockbuster drugs have expired, the industry-feeling the pinch-has focused its attention on intellectual property. Because every additional month of market exclusivity can mean an extra $50 million or more in revenue, pharma companies have gone to great lengths to block the entry of generic competition.
Latest:
India: An Emerging Knowledge Superpower"India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making.
Latest:
Drug Promotion to Docs on the DefensiveCanberra, Australia-The Australian Pharmaceutical Manufacturers' Association has denounced calls from the country's media and some of its doctors to drastically curtail drug promotion. APMA chief executive Alan Evans says any such move would severely affect the healthcare of millions of people in Australia and could even result in premature death.
Latest:
Patient Input and Patient Preference StudiesPatient preferences are increasingly seen as valuable in healthcare policy decision-making, but such studies are not always easy to design and implement, writes Nick Hicks.
Latest:
How Pharma’s Checks and Balances Can Help Fight Its Public PerceptionWhat can we do to prevent such blatant black eyes to the industry so many of us love?
Latest:
Legal: Foreign PolicyCompliance requires overcoming cultural barriers. To start with, in some countries the taboo against bribery is not as strong as it is here.
Latest:
Finding the Translators: Helping Connect the Science to the PatientThe need for analytics translators is not limited to data science. The adoption of all scientific or technical advances, including those in the healthcare industry, needs effective translators. So what does this mean for pharma marketing?
Latest:
Ten Minutes to ConnectHow one conversation between a woman and her physician can make or break a brand
Latest:
The Road to Nowhere?Drug companies can do to specialists what Intel did to PC box makers: commoditize them.
Latest:
Introduction: Minding MoralsWHEN I WAS GROWING UP, my favorite book was Aesop's Fables. I especially loved the way every story had a moral at the end to tie everything together: Try before you trust; the hero is brave in deeds as well as words; birds of a feather flock together; might makes right; don't be the boy who cried wolf. Those one-line messages packed a punch then, and still stick with me.
Latest:
Exponential Medicine and Pharma's Unfulfilled PromiseBill Drummy reviews the "techno-optimistic" highlights of this year's Exponential Medicine conference in San Diego.
Latest:
Biopharma Business Check: Financing Review and OutlookA look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.
Latest:
Track Patients, Not PrescriptionsEven though data can single out physicians with high marketing upsides, most pharma companies are doing without such high-value data.
Latest:
Meetings: Doctor ConsultationMeetings at which peripheral activities become the focal point are likely to attract scrutiny.
Latest:
A New Game Plan for Pharma HRNew dynamics are forcing the industry's human resource departments to rethink their operational game plans. The drivers-consolidation, globalization, scientific advances, public policy, and competition-have pushed HR leaders into new territory to address business needs.
